// App-Quantinova.ai

14849 : Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME

Researchers

Presenter

  • Muthiah Vaduganathan

Principal Investigators

  • Naveed Sattar

  • David H Fitchett

  • Anne Pernille Ofstad

  • Martina Brueckmann

  • Jyothis T George

  • Subodh Verma

  • Michaela Mattheus

  • Christoph Wanner

  • Silvio E Inzucchi

  • Bernard Zinman

  • Javed Butler

Medical Centers

  • Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • University of Glasgow, Glasgow, United Kingdom

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

  • Med Dept, Boehringer Ingelheim KS, Asker, Norway

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Div of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hosp, Univ of Toronto, Toronto, Canada

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Dept of Internal Medicine I, Nephrology, Univ Hosp Würzburg, Würzburg, Germany

  • Section of Endocrinology, Yale Univ Sch of Medicine, Yale-New Haven Hosp, New Haven, CT

  • Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, Ontario, Canada

  • Dept of Medicine, Univ of Mississippi, Jackson, MS

Locations

  • United States

  • United Kingdom

  • Canada

  • Norway

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • Insulin

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved